Home  /  Resource Library  /  ACALABRUTINIB IN TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA: MATURE RESULTS FROM PHASE 2 STUDY DEMONSTRATING DURABLE REMISSIONS AND LONG-TERM TOLERABILITY

ACALABRUTINIB IN TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA: MATURE RESULTS FROM PHASE 2 STUDY DEMONSTRATING DURABLE REMISSIONS AND LONG-TERM TOLERABILITY

EHA 2020: Long term results of a study examining acalabrutinib for first line treatment of CLL.